profit from every $100 of sales.
$0$100
China SXT Pharmaceuticals
$2.88-7.10% today
-95.7% in 1 year
1-year low $2.781-year high $536.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What China SXT Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $2.60 million in 2022 to $1.74 million in 2025, with -$3.30 million of profit last year.
SalesProfit
China SXT Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| China SXT Pharmaceuticals | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.3× · Very expensive | ||
 Galderma Group | 87.0× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.1× · Expensive |
AI analysis
An AI analyst reads China SXT Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3 | 2 | 2 | 2 | |
| 1 | 0 | 1 | 0 | |
| -5 | -6 | -3 | -3 | |
| -5 | -5 | -2 | -3 | |
| -6 | -6 | -3 | -3 | |
| -85,613.36 | -15,576.83 | -1,676.69 | -348.15 | |
| 48.1% | 21.6% | 28.7% | 21.1% | |
| -199.4% | -284.4% | -130.4% | -154.0% | |
| -220.4% | -301.0% | -160.7% | -189.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 34 | 30 | 23 | 22 |
| Cash | 16 | 17 | 12 | 18 |
| Total debt | 2 | 4 | 3 | 1 |
| Total liabilities | 17 | 15 | 9 | 6 |
| 16 | 15 | 14 | 15 | |
| 0 | 0 | 0 | 0 | |
| -23.0% | -23.4% | -12.2% | -12.8% | |
| -34.9% | -40.4% | -22.2% | -21.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | -0 | -2 | -2 | |
| 0 | 0 | 0 | 0 | |
| 0 | -0 | -2 | -2 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 0 | 0 |
Valuation
- –
- –
- –
- 0.2×
- 0.2×
- –
- –
- -786.9%
- -1,107.5%
- 0.0%
Profitability
- 21.1%
- -154.0%
- -189.8%
- -222.6%
- -9.5%
- -23.8%
- -14.7%
- -9.5%
- -10.0%
- –
Growth
- −12.5%
- –
- −21.3%
- –
- +93.6%
Financial health
- -6.7×
- 0.06
- 4.6%
- -4.4×
- 4.37
- 4.24
- 0.03
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 27%of 953
Bottom 2%of 877
Bottom 7%of 871
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 31, 2022 | 2.23 | – | – |
| Mar 31, 2021 | 0.37 | – | – |
| Sep 30, 2020 | 0.03 | – | – |
| Mar 31, 2020 | -0.42 | – | – |
| Mar 31, 2019 | 0.07 | – | – |
| Sep 30, 2018 | 0.05 | – | – |
| Mar 31, 2018 | 0.01 | – | – |
| Dec 31, 2017 | 0.04 | – | – |
News
The next AI battleground is compute, and China has a cost advantageSeeking Alpha · Nov 11, 2026A Short Seller Says China Drove “Over 20%” of Nvidia’s Compute Sales. Why Nvidia’s “Under 1%” Doesn’t Settle ItYahoo Finance · Nov 11, 2026China optical stocks rally as Microsoft challenges proposed U.S. import curbsYahoo Finance · Nov 11, 2026Nvidia could soon face tougher export rules, making it harder to sell chips to China after scandalMarketWatch · Nov 10, 2026AI chip exports to China and oversight bills gain momentum in CongressYahoo Finance · Nov 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
78Pass
Philip Fisher
28No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
23No pass
Questions about China SXT Pharmaceuticals
Is China SXT Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the China SXT Pharmaceuticals AI analysis
What does China SXT Pharmaceuticals do?
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. It is in Drug Manufacturers - Specialty & Generic.
Does China SXT Pharmaceuticals pay a dividend?
No. China SXT Pharmaceuticals does not pay a dividend at the moment.
Is China SXT Pharmaceuticals stock halal?
No. China SXT Pharmaceuticals does not pass our halal screen: its debt is 330% of its market value, at or above the 33% limit. How we check
How has China SXT Pharmaceuticals stock done over the past year?
Down 95.7% over the past twelve months, to $2.88. It traded between $2.78 and $536.00 and is 99.5% below its high.
Who are China SXT Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with China SXT Pharmaceuticals's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.